Tags

Type your tag names separated by a space and hit enter

Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Prostate 2009; 69(12):1303-11P

Abstract

BACKGROUND

Recent epidemiologic studies have identified obesity as a risk factor for benign prostatic hyperplasia (BPH). We examined whether adiponectin, leptin, and C-peptide were associated with incident, symptomatic BPH and whether these factors mediate the relationship between obesity and BPH risk.

METHODS

Data are from Prostate Cancer Prevention Trial placebo arm participants who were free of BPH at baseline. Incident BPH (n = 698) was defined as treatment, two International Prostate Symptom Score (IPSS) values > 14, or an increase of >or=5 in IPSS from baseline documented on at least two occasions plus at least one score >or=12. Controls (n = 709) were selected from men reporting no BPH treatment or IPSS > 7 during the 7-year trial. Baseline serum was analyzed for adiponectin, C-peptide, and leptin concentrations.

RESULTS

Neither C-peptide nor leptin was associated with BPH risk. The odds ratio [95% CI] contrasting highest to lowest quartiles of adiponectin was 0.65[0.47, 0.87] P(trend) = 0.004. Findings differed between levels of physical activity: there was a strong inverse association between adiponectin and BPH among moderately/very active men OR = 0.43 [0.29, 0.63], and no association among sedentary/minimally active men OR = 0.92 [0.65, 1.30] P(interaction) = 0.005. Adiponectin concentrations explained only a moderate amount of the relationship between obesity and BPH risk.

CONCLUSIONS

High adiponectin concentrations were associated with reduced risk of incident, symptomatic BPH. This association was limited to moderately/very active men; suggesting the relationship between obesity and BPH involves a complex interaction between factors affecting glucose uptake and insulin sensitivity. However, adiponectin is likely not the only mechanism through which obesity affects BPH risk.

Authors+Show Affiliations

Fred Hutchinson Cancer Research Center, Cancer Prevention Program, Seattle, Washington 98109-1024, USA. jschenk@fhcrc.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

19475640

Citation

Schenk, Jeannette M., et al. "Serum Adiponectin, C-peptide and Leptin and Risk of Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial." The Prostate, vol. 69, no. 12, 2009, pp. 1303-11.
Schenk JM, Kristal AR, Neuhouser ML, et al. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Prostate. 2009;69(12):1303-11.
Schenk, J. M., Kristal, A. R., Neuhouser, M. L., Tangen, C. M., White, E., Lin, D. W., & Thompson, I. M. (2009). Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. The Prostate, 69(12), pp. 1303-11. doi:10.1002/pros.20974.
Schenk JM, et al. Serum Adiponectin, C-peptide and Leptin and Risk of Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial. Prostate. 2009 Sep 1;69(12):1303-11. PubMed PMID: 19475640.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. AU - Schenk,Jeannette M, AU - Kristal,Alan R, AU - Neuhouser,Marian L, AU - Tangen,Catherine M, AU - White,Emily, AU - Lin,Daniel W, AU - Thompson,Ian M, PY - 2009/5/29/entrez PY - 2009/5/29/pubmed PY - 2009/8/6/medline SP - 1303 EP - 11 JF - The Prostate JO - Prostate VL - 69 IS - 12 N2 - BACKGROUND: Recent epidemiologic studies have identified obesity as a risk factor for benign prostatic hyperplasia (BPH). We examined whether adiponectin, leptin, and C-peptide were associated with incident, symptomatic BPH and whether these factors mediate the relationship between obesity and BPH risk. METHODS: Data are from Prostate Cancer Prevention Trial placebo arm participants who were free of BPH at baseline. Incident BPH (n = 698) was defined as treatment, two International Prostate Symptom Score (IPSS) values > 14, or an increase of >or=5 in IPSS from baseline documented on at least two occasions plus at least one score >or=12. Controls (n = 709) were selected from men reporting no BPH treatment or IPSS > 7 during the 7-year trial. Baseline serum was analyzed for adiponectin, C-peptide, and leptin concentrations. RESULTS: Neither C-peptide nor leptin was associated with BPH risk. The odds ratio [95% CI] contrasting highest to lowest quartiles of adiponectin was 0.65[0.47, 0.87] P(trend) = 0.004. Findings differed between levels of physical activity: there was a strong inverse association between adiponectin and BPH among moderately/very active men OR = 0.43 [0.29, 0.63], and no association among sedentary/minimally active men OR = 0.92 [0.65, 1.30] P(interaction) = 0.005. Adiponectin concentrations explained only a moderate amount of the relationship between obesity and BPH risk. CONCLUSIONS: High adiponectin concentrations were associated with reduced risk of incident, symptomatic BPH. This association was limited to moderately/very active men; suggesting the relationship between obesity and BPH involves a complex interaction between factors affecting glucose uptake and insulin sensitivity. However, adiponectin is likely not the only mechanism through which obesity affects BPH risk. SN - 1097-0045 UR - https://www.unboundmedicine.com/medline/citation/19475640/Serum_adiponectin_C_peptide_and_leptin_and_risk_of_symptomatic_benign_prostatic_hyperplasia:_results_from_the_Prostate_Cancer_Prevention_Trial_ L2 - https://doi.org/10.1002/pros.20974 DB - PRIME DP - Unbound Medicine ER -